A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).

PHASE4CompletedINTERVENTIONAL

Enrollment

130

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

August 30, 2024

Study Completion Date

August 30, 2024

Conditions

Metastatic Breast Cancer

Interventions

DRUG

Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)

Drug intervention

Trial Locations (1)

Agaplesion Markus Krankenhaus - Klinik für Gynäkologie und Geburtshilfe, Frankfurt am Main